In this paper, we develop a predictive computational framework that aims to advance our current understanding of the differential impact of IL-6 on CSC self-renewal and HNSCC growth and investigate the mechanisms of tumor reduction associated targeted treatment with the anti-IL-6R antibody Tocilizumab. Here, IL6R is linked to head and neck squamous cell carcinoma.